New hope for rare gut cancers: triple-drug combo shows promise
NCT ID NCT05472948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (surufatinib, sintilimab, and capecitabine) in people with advanced small bowel or appendix cancer that has spread and stopped responding to standard treatments. The goal is to see if this mix can shrink tumors or slow cancer growth. About 36 adults will take part, and the study will also find the safest dose of surufatinib when given with the other two drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF SMALL INTESTINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study aims to close gaps in cancer care for black patients
- New CAR-T therapy aims to outsmart Hard-to-Treat solid cancers
- New combo aims to wipe out hidden breast cancer cells after standard treatment
- New drug cocktail aims to outsmart ALK lung cancer
- Promising drug cocktail targets Hard-to-Treat cervical cancer
- Can acupuncture and ice chips beat chemo nerve damage?